Riding on positive PhIII NASH data, Madrigal raises $300M for road to FDA
Madrigal Pharmaceuticals isn’t wasting any time capitalizing on its big NASH win, hauling in more than $300 million to push the program forward.
The biotech’s shares had doubled after it reported that its NASH drug, resmetirom, met its early endpoints in a Phase III trial, marking a rare success in a field littered with failures. Execs said they plan to file for accelerated approval early next year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.